Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 10, 2018Data Support Minimally Invasive Single-Incision Mesh Procedure as a Durable, Safe and Effective Treatment for Stress Urinary Incontinence, a Condition that Affects 18 Million American Adults
CHICAGO and MARLBOROUGH, Mass., Oct. 10, 2018 -- Boston Scientific Corporation (NYSE: BSX) today announced that its Solyx™ Single Incision Sling (SIS) System achieved treatment success, meeting...
-
Oct 1, 2018Fourth annual Connected Patient Challenge focuses on utilizing population health data, patient monitoring or predictive analytics to improve patient care and lower healthcare costs
MARLBOROUGH, Mass., Oct. 1, 2018– Boston Scientific Corporation (NYSE: BSX) today announced a worldwide call for submissions to the fourth annual Boston Scientific Connected Patient Challenge,...
-
Oct 1, 2018
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2018 on Wednesday, October...
-
Sep 24, 2018First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease
Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™ Drug-Eluting Vascular...
-
Sep 22, 2018First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries
Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were...